Innoviva Inc   (INVA)
Other Ticker:  
Price: $15.5200 $0.04 0.258%
Day's High: $15.66 Week Perf: -1.77 %
Day's Low: $ 15.27 30 Day Perf: -6.05 %
Volume (M): 1,428 52 Wk High: $ 16.87
Volume (M$): $ 22,163 52 Wk Avg: $13.43
Open: $15.45 52 Wk Low: $10.64

 Market Capitalization (Millions $) 1,337
 Shares Outstanding (Millions) 86
 Employees 540
 Revenues (TTM) (Millions $) 273
 Net Income (TTM) (Millions $) 278
 Cash Flow (TTM) (Millions $) -104
 Capital Exp. (TTM) (Millions $) 0

Innoviva Inc
Innoviva Inc (formerly known as Theravance Inc) is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies for respiratory diseases. The company was founded in 1996 and is headquartered in South San Francisco, California, with additional offices in various countries around the world.

Innoviva's mission is to improve the lives of patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, among others. The company's focus is on developing new and more effective ways of delivering drugs to the lungs, which can be a challenging task due to the complex structure of this organ.

One of the main products developed by Innoviva is the Ellipta inhaler, which is used for the treatment of COPD and asthma. This inhaler uses a proprietary dry powder delivery technology that makes it easier for patients to inhale the medication and ensures that the drug reaches the lungs in sufficient quantities to achieve therapeutic effect.

In addition to the Ellipta inhaler, Innoviva has a range of other respiratory drugs in its pipeline, including several in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim. These drugs are in various stages of clinical development and are aimed at addressing the unmet needs of patients suffering from a range of respiratory diseases.

Apart from its focus on respiratory disease therapies, Innoviva also has a strong commitment to environmental sustainability. The company places great emphasis on reducing its carbon footprint and has adopted various measures to achieve this goal, such as minimizing waste generation, reducing energy consumption, and promoting the use of renewable energy sources.

Overall, Innoviva Inc has established a strong reputation for its innovative respiratory disease therapies and its commitment to environmental sustainability. The company's continued focus on R&D, collaboration with major pharmaceutical companies, and its dedication to improving patient outcomes makes it a key player in the biopharmaceutical industry.

   Company Address: 1350 Old Bayshore Highway, Suite 400 Burlingame 94010 CA
   Company Phone Number: 238-9600   Stock Exchange / Ticker: NASDAQ INVA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Biomarin Pharmaceutical Inc

2 Subtitle options:Shareholders Disappointed as Biomarin Pharmaceutical Inc Reports Stagnant Earnings Despite Revenue Surge2.

Surge in Revenue Fails to Boost Earnings for Biomarin Pharmaceutical Inc in Q4 2023
Investors were taken by surprise as major pharmaceutical preparations company, Biomarin Pharmaceutical Inc (BMRN), reported stagnant earnings despite a substantial increase in revenue during the fourth quarter of the 2023 earnings season. Net profit per share remained unchanged at $0.11, marking a disappointment for shareholders.
BMRN's revenue, however, experienced a significant jump of 20.216% to $646.21 million compared to the same quarter in the previous year. This growth is noteworthy, especially considering the overall major pharmaceutical preparations sector experienced a decline of -15.67% in top-line revenue. Reflecting on the industry's performance, BMRN stands out with its revenue growth.

Organon And Co

Rapid Revenue Growth Fueled by $442M Boost in Income Tax Provisions

In a recent news development, pharmaceutical giants Organon and Eli Lilly have announced a strategic partnership aimed at revolutionizing the migraine medication market in Europe. Organon, known for its focus on women's health, will now become the exclusive distributor and promoter of two premium migraine medicines - Emgality (Galcanezumab) and RAYVOW (Lasmiditan) across the region.
This collaboration comes at a crucial time for Organon as the company faces declining revenues. In the third quarter of 2023, Organon reported a year-on-year revenue decrease of 1.17%, reflecting the challenging commercial landscape in the pharmaceutical industry. This decline was potentially faster than that experienced by its competitors. However, it is worth noting that Organon maintained a positive net margin of 3.82%, indicating its ability to generate a profit after covering all costs.

Beigene Ltd

Beigene Ltd Reports $-0.27 Deficit per Share Amid Positive CHMP Opinion for Tislelizumab2.

BeiGene, a global oncology company, has recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for their drug Tislelizumab as a treatment for non-small cell lung cancer (NSCLC). This approval includes three indications in combination therapy, offering potential improvements in treatment options for NSCLC patients.
The CHMP opinion recommends the approval of Tislelizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of NSCLC. This innovative combination therapy highlights BeiGene's dedication to enhancing patient outcomes. By targeting the programmed death-ligand 1 (PD-L1) pathway, Tislelizumab has shown promising results in clinical trials, opening up possibilities for treating NSCLC patients.

Elanco Animal Health Inc

Elanco Animal Health Inc Faces Deficit Despite Revenue Growth in Fiscal Fourth Quarter 2023

The recent financial results of Elanco Animal Health Inc for the fiscal fourth quarter of 2023 have caught the attention of investors and industry experts alike. The company's performance, unlike its peers in the Major Pharmaceutical Preparations industry, saw a substantial improvement in revenue growth and earnings per share. Furthermore, amidst concerns about methane emissions from livestock, Elanco Animal Health has partnered with Athian, a leading technology company, to develop innovative solutions that address this environmental challenge. This article interprets the financial results and explores the potential implications for Elanco Animal Health going forward.
Revenue Growth and Earnings:
In the fiscal fourth quarter of 2023, Elanco Animal Health witnessed a remarkable 5.505% increase in revenue, reaching $1.04 billion compared to $981.00 million in the same period a year ago. This growth is particularly noteworthy when contrasted with the Major Pharmaceutical Preparations industry, which experienced a significant decline of -15.67% in business. Moreover, earnings per share improved from $-2.22 per share in the previous reporting period, indicating a positive trajectory for the company. Although a quarterly deficit of -$0.28 per share was recorded, it is important to note that this represents an improvement compared to -$0.11 per share a year ago.


Sanofi's Shares See Decline, But Collaboration with Innate Pharma Sparks Hope for Future Growth

Sanofi, a major pharmaceutical preparations company, has been experiencing a decline in its shares over the past 30 days. With a decrease of -10.99% in its share price, the year-to-date performance has been affected, reaching -7.64%. Additionally, the company's shares are trading only 8.3% above its 52-week low. However, despite these challenges, Sanofi recently announced a significant milestone in its collaboration with Innate Pharma, a leading biotechnology company.
Innate Pharma disclosed that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate's innovative ANKET platform. This collaboration aims to harness the power of the immune system to fight cancer, which is a highly sought-after area for innovative cancer treatments. This development is a crucial step forward in the quest for effective cancer therapies.


Innoviva Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com